Davide Perrella

At Novo Nordisk, we inextricably link our commitment to improving quality of life with innovation, sustainability, and a strong dedication to social responsibility.   It is with pride that we announce the launch of the Vulnerable Project today. An initiative that, for the first time in Italy and Europe, addresses patients defined as "invisible": individuals who often remain on the fringes without access to the assistance they need.   ‘Vulnerable’ responds to the care needs of the most fragile diabetes patients. Through our collaboration with Banco Farmaceutico, we will provide free insulin and therapy administration devices to the social assistance organizations that will take care of indigent individuals with diabetes. A commitment that starts today and will continue in the future.

128

2 commenti

Italian biopharma group Chiesi Group is planning to invest over €400 million on a site near Milan to boost production. The company is seeking to grow organically and through M&A. Our latest:

145

1 commento

A promising start for the Italian pharmaceutical market in 2025: in the first three weeks of the year, the sector recorded significant growth, reflecting a continuous commitment to innovation and the development of increasingly effective healthcare solutions.   An interesting insight? The evolution of pharmaceutical spending goes hand in hand with medical progress: from increased life expectancy to the rise of personalized medicine, new therapeutic approaches are transforming the way we take care of our health.   This trend confirms the crucial role of the sector in ensuring increasingly targeted and accessible treatments, supporting people’s well-being at every stage of life. Monitoring these changes will be essential to seize the opportunities of an innovation-driven future, where health and quality of life take center stage. https://lnkd.in/dBFXmBhg

80

A €1.2bn boost to the Italian pharmaceutical budget in 2026 has been promised by Health Minister Orazio Schillaci. However, pricing reform will also be required.   The growth in spending on medicines will be part of a €6bn increase to the total healthcare fund in 2026. Other priorities will include recruiting additional staff, investing more in prevention to meet the needs of an ageing population and allocating additional funds to the new mental health plan, with a focus on young people.   The increase in the overall healthcare budget will add €500mn to the pharmaceutical spending cap, which is calculated as a percentage of total expenditure on healthcare. In addition, the government plans to raise that percentage by half a percentage point, which will boost the allowance by a further €700mn.   In return, the government will be looking to make significant changes to how drugs are priced in Italy. The Minister told La Stampa newspaper: “We must also accelerate the renegotiation of prices for older drugs and reform the pricing system, basing it on real post-marketing efficacy data.” Details are lacking, but Schillaci’s comments clearly suggest a more dynamic approach to pricing across the product life cycle.   It would be interesting to know to what extent the Italian government’s decision to raise pharmaceutical expenditure is influenced by recent pressure from the Trump administration for affluent countries in Europe to spend a larger percentage of their GDP on newer prescription drugs. Recent reports suggest the UK government will soon announce plans to raise expenditure on innovative medicines as a percentage of GDP closer to US levels (tinyurl.com/y62kbaap).   Intensifying measures to contain spending on older drugs would help to offset increased costs for newer medicines, though governments would have to beware of exerting pressure that could drive products out of the market. Policymakers at national and EU level are currently wrestling with the challenges of attracting production of critical medicines back to Europe in the interests of strategic autonomy and security of supply—and pricing will be a critical factor in the feasibility of relocation (tinyurl.com/5n7pes5p). #Italy #pharmaceutical #expenditure #drugpricing

89

As part of our PDA Italy Chapter upcoming event 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮’𝘀 𝗖𝗼𝗹𝗱 #𝗦𝘂𝗽𝗽𝗹𝘆𝗖𝗵𝗮𝗶𝗻, hosted in partnership with KW Apparecchi Scientifici srl and taking place on 𝗠𝗮𝘆 𝟭𝟱–𝟭𝟲 𝗶𝗻 𝗦𝗶𝗲𝗻𝗮, we are pleased to introduce Odra Pinato, Head of TEC Analytics – EMEA at Stevanato Group , among the event’s speakers. Odra will share key findings on how #packaging materials and configurations respond to extreme temperatures. 🌡️   Her talk, "𝘊𝘰𝘮𝘱𝘢𝘵𝘪𝘣𝘪𝘭𝘪𝘵𝘺 𝘰𝘧 𝘨𝘭𝘢𝘴𝘴 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘦𝘳𝘴 𝘸𝘪𝘵𝘩 𝘤𝘰𝘭𝘥 𝘴𝘵𝘰𝘳𝘢𝘨𝘦 𝘤𝘰𝘯𝘥𝘪𝘵𝘪𝘰𝘯𝘴: 𝘤𝘩𝘢𝘳𝘢𝘤𝘵𝘦𝘳𝘪𝘻𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘬𝘦𝘺 𝘢𝘵𝘵𝘳𝘪𝘣𝘶𝘵𝘦𝘴", will highlight the results of in-depth studies on glass vial performance and container closure integrity after prolonged exposure to –80°C — a critical topic for ensuring product safety, avoiding loss, and managing cost risks in pharmaceutical production.   📍𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗦𝗶𝗲𝗻𝗮 and take part in two days of knowledge-sharing, discussion, and industry insight: https://lnkd.in/d8grH47Y

66

2 commenti

🧠 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐁𝐫𝐚𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 I’m proud to share that Angelini Pharma is financing a newly established academic Chair in Brain Health at the Universiteit Gent for an initial period of three years. This chair will serve as the foundation for an innovative research project aimed at advancing new approaches in brain health — spanning prevention, early detection, and care. The initiative links academic research and industry expertise to address one of the most pressing challenges in public health in a novel way that, to our knowledge, has no current equivalent in Europe. As Chief Medical Officer, I see this as part of a broader effort to rethink how we invest in sustainable, high-impact science, focused on real-world outcomes for patients and society. Looking forward to what this collaboration with the Ghent team will make possible. Kristl Vonck, Paul Boon, Rafal Kaminski, Rik Van de Walle #BrainHealth #Neuroscience #UGent #AngeliniPharma

201

2 commenti